Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 3-year Results from the Open-Label Extension of the Randomised Controlled Phase 3 SELECT-PsA 2 Study

Clin Exp Rheumatol. 2023 doi: 10.55563/clinexprheumatol/8l7bbk. Epub ahead of print

Data from this open-label extension showed the efficacy of upadacitinib observed at 56 weeks was maintained through to 152 weeks in the treatment of patients with PsA. No cumulative adverse effects were observed, and no new safety signals were identified.

While there are currently a wide range of treatments for PsA available, some patients still fail to achieve their treatment targets. The SELECT-PsA 2 study showed upadacitinib 15 mg and 30 mg was significantly more effective than the placebo in the treatment of patients with PsA through to 56 weeks. The results of the SELECT-PSA 2 open-label extension study provided much needed long-term data on patients with PsA and supports the favourable safety profile of upadacitinib.